Comparative Pharmacology
Head-to-head clinical analysis: ANDROID 10 versus FORTESTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDROID 10 versus FORTESTA.
ANDROID 10 vs FORTESTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Androgen receptor agonist; testicular androgen responsible for development and maintenance of male sex characteristics and anabolic effects; increases protein synthesis and muscle mass.
Testosterone replacement therapy; testosterone binds to and activates androgen receptors, influencing gene transcription and protein synthesis, leading to the development of male secondary sex characteristics and maintenance of libido, muscle mass, and bone density.
Testosterone undecanoate 750 mg (3 mL) intramuscular injection every 10 weeks, or testosterone cypionate 50-400 mg intramuscular injection every 2-4 weeks. For gel formulations: 50-100 mg transdermally once daily.
Apply one 30 mg metered-dose transdermal system to abdomen or upper arm once daily at the same time each day.
None Documented
None Documented
8 hours; clinical context: steady-state achieved in 2-3 days, dosing interval 8-12 hours.
Terminal elimination half-life is 3–4 hours; not clinically significant for once-daily transdermal administration due to sustained absorption.
Renal: 90% as glucuronide and sulfate conjugates, 6% as unchanged drug; fecal: 4%.
Primarily renal (90% as glucuronide and sulfate conjugates, 10% unchanged); approximately 1% fecal.
Category C
Category C
Androgen
Androgen